Last updated: July 17, 2026

Application No. 18/613,203

Small Molecule Targeting of BRD4 for Treatment of COVID-19

Non-Final OA

Filed

Mar 22, 2024

Priority

Mar 24, 2023 — provisional 63/454,511

Examiner

HEES, OLIVER DRAGON

Art Unit

1628

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Board of Regents of the University of Texas System

OA Round

1 (Non-Final)

Interview Optional

— +0.0% interview lift. Interview lift (+0.0%) is below the 15.0% threshold. A written response is recommended.

Based on 1 resolved cases, 2023–2026

Examiner Intelligence

HEES, OLIVER DRAGON View full profile →

Grants 100% — above average

Career Allowance Rate

1 granted / 1 resolved

+40.0% vs TC avg

Minimal +0% lift

Without

With

+0.0%

Interview Lift

resolved cases with interview

Typical timeline

2y 8m

Avg Prosecution

33 currently pending

Career history

Total Applications

across all art units

Statute-Specific Performance

§103

48.0%

+8.0% vs TC avg

§102

10.0%

-30.0% vs TC avg

§112

22.0%

-18.0% vs TC avg

Black line = Tech Center average estimate • Based on career data from 1 resolved cases

Prosecution Timeline

Mar 22, 2024

Application Filed

May 06, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

18/263,626

Patent 12643922

URSOLIC ACID PREPARATIONS AND USES THEREOF

2y 10m to grant Granted Jun 02, 2026

Study what changed to get past this examiner. Based on 1 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

100%

Grant Probability

99%

With Interview (+0.0%)

2y 8m (~4m remaining)

Median Time to Grant

Low

PTA Risk

Based on 1 resolved cases by this examiner. Grant probability derived from career allowance rate.